Premium Nahrungsergänzungsmittel | artgerecht

Somatropin – Human Growth Hormone Uses & Effects

Somatropin is a synthetically produced human growth hormone used in medicine to treat growth disorders and hormone deficiency.

Regular tips about health Regular tips about health

Things worth knowing about "Somatropin"

Somatropin is a synthetically produced human growth hormone used in medicine to treat growth disorders and hormone deficiency.

What is Somatropin?

Somatropin is the recombinant (synthetically produced) form of human growth hormone (HGH), also known as somatotropin. It is manufactured using recombinant DNA technology and is structurally identical to the growth hormone naturally produced by the human body. In the body, growth hormone is secreted by the pituitary gland and plays a key role in growth, metabolism, and body composition.

Indications

Somatropin is approved for use in several medically recognized conditions, including:

Growth hormone deficiency in children and adults: When the pituitary gland does not produce sufficient growth hormone
Short stature due to Turner syndrome: A genetic condition affecting females
Prader-Willi syndrome: A genetic developmental disorder
Chronic renal insufficiency in children: Growth failure caused by kidney disease
Small for Gestational Age (SGA): Children born small who fail to show catch-up growth
HIV-associated lipodystrophy: Abnormal body fat distribution in HIV-positive patients

Mechanism of Action

Somatropin exerts its effects through two main pathways:

Direct Effects

Somatropin binds directly to growth hormone receptors in various tissues, including adipose (fat) tissue and the liver. This promotes fat breakdown (lipolysis) and helps regulate glucose metabolism.

Indirect Effects via IGF-1

The most important mechanism involves the liver: somatropin stimulates hepatic production of Insulin-like Growth Factor 1 (IGF-1). IGF-1 mediates most of the growth-promoting effects of somatropin, in particular the stimulation of chondrocytes (cartilage cells) in the growth plates of long bones, leading to linear growth in children.

Dosage and Administration

Somatropin is administered as a subcutaneous injection (under the skin), typically once daily, preferably in the evening. The dose is determined by the treating physician based on the indication, body weight, and individual response. For children with growth hormone deficiency, a typical dose is approximately 0.025–0.035 mg/kg body weight per day.

Side Effects

Like all medications, somatropin can cause side effects. Commonly reported side effects include:

Fluid retention (peripheral oedema)
Joint pain (arthralgia) and muscle pain (myalgia)
Headaches
Injection site reactions (redness, swelling)
Elevated blood glucose levels (insulin resistance)
Carpal tunnel syndrome in adults
In rare cases: raised intracranial pressure (intracranial hypertension)

In children, there is a slightly increased risk of developing scoliosis (spinal curvature) and slipped capital femoral epiphysis.

Contraindications

Somatropin must not be used in patients with:

Active malignant disease (cancer)
Severe obesity or serious respiratory problems in Prader-Willi syndrome
Hypersensitivity to the active substance
Closed growth plates (except in adults with growth hormone deficiency)
Acute life-threatening conditions

Drug Interactions

Somatropin can interact with several other medications. Clinically relevant interactions include:

Corticosteroids: May inhibit the growth-promoting effects of somatropin
Insulin and antidiabetics: Dose adjustments may be necessary, as somatropin can reduce insulin sensitivity
Thyroid hormones: Existing hypothyroidism should be treated before starting somatropin therapy
Sex hormones (e.g. oestrogens): Can influence IGF-1 production and somatropin efficacy

References

European Medicines Agency (EMA): Product information for authorised somatropin-containing medicines. www.ema.europa.eu
Growth Hormone Research Society: Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone Deficiency in Childhood and Adolescence. Journal of Clinical Endocrinology & Metabolism, 2000.
Laron Z. - Insulin-like growth factor 1 (IGF-1): a growth hormone. Molecular Pathology, 2001; 54(5): 311–316.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.